Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV

Following the market withdrawal of Pfizer’s Oxbryta, demand rises for sickle cell therapies with global potential

Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 

Cambridge, Mass. newco debuts with $125M, A round led by Cormorant to bring CRISPR to the epigenome

Plus: OncoCyte, MISER, GSK and more

Genentech’s faricimab meets in Phase III diabetic macular edema trialsThe Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said faricimab met its primary endpoint of non-inferior visual

A side-by-side look at new AML therapies